阿尼芬淨 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "阿尼芬淨" in Chinese language version.

refsWebsite

Global rank Chinese rank

12web.archive.org

1^st place

11nih.gov

4^th place

5^th place

11doi.org

2^nd place

23^rd place

5archive.org

6^th place

4^th place

2rxlist.com

7,927^th place

5,088^th place

2prnewswire.com

406^th place

918^th place

2fda.gov

447^th place

581^st place

2europa.eu

68^th place

209^th place

1who.int

195^th place

179^th place

1pfizer.com

low place

7,863^rd place

1drugs.com

399^th place

208^th place

1handle.net

102^nd place

492^nd place

1manchester.ac.uk

4,003^rd place

4,603^rd place

1semanticscholar.org

11^th place

332^nd place

1harvard.edu

18^th place

57^th place

archive.org

Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrobial Agents and Chemotherapy. June 2004, 48 (6): 2021–2024. PMC 415613 . PMID 15155194. doi:10.1128/AAC.48.6.2021-2024.2004.
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Journal of Clinical Microbiology. November 2005, 43 (11): 5425–5427. PMC 1287823 . PMID 16272464. doi:10.1128/JCM.43.11.5425-5427.2005.
Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrobial Agents and Chemotherapy. November 2005, 49 (11): 4795–4797. PMC 1280139 . PMID 16251335. doi:10.1128/AAC.49.11.4795-4797.2005.
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. American Journal of Health-System Pharmacy. April 2005, 62 (8): 834–837. PMID 15821277. doi:10.1093/ajhp/62.8.834 .
Shao L, Li J, Liu A, Chang Q, Lin H, Chen D. Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains. Applied and Environmental Microbiology. February 2013, 79 (4): 1126–1133. Bibcode:2013ApEnM..79.1126S. PMC 3568618 . PMID 23220968. doi:10.1128/AEM.02792-12.

doi.org

Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrobial Agents and Chemotherapy. June 2004, 48 (6): 2021–2024. PMC 415613 . PMID 15155194. doi:10.1128/AAC.48.6.2021-2024.2004.
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Journal of Clinical Microbiology. November 2005, 43 (11): 5425–5427. PMC 1287823 . PMID 16272464. doi:10.1128/JCM.43.11.5425-5427.2005.
Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrobial Agents and Chemotherapy. November 2005, 49 (11): 4795–4797. PMC 1280139 . PMID 16251335. doi:10.1128/AAC.49.11.4795-4797.2005.
Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and Outcomes Research. January 2017, 9: 39–47. PMC 5221484 . PMID 28115858. doi:10.2147/CEOR.S122177 .
Zida A, Bamba S, Yacouba A, Ouedraogo-Traore R, Guiguemdé RT. Anti-Candida albicans natural products, sources of new antifungal drugs: A review. Journal de Mycologie Médicale. March 2017, 27 (1): 1–19. PMID 27842800. doi:10.1016/j.mycmed.2016.10.002.
Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. European Journal of Medical Research. April 2011, 16 (4): 159–166. PMC 3352072 . PMID 21486730. doi:10.1186/2047-783x-16-4-159 .
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. American Journal of Health-System Pharmacy. April 2005, 62 (8): 834–837. PMID 15821277. doi:10.1093/ajhp/62.8.834 .
Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clinical Therapeutics. June 2005, 27 (6): 657–673. PMID 16117974. doi:10.1016/j.clinthera.2005.06.010.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (PDF). Clinical Infectious Diseases. February 2008, 46 (3): 327–360 [2024-07-25]. PMID 18177225. S2CID 8789905. doi:10.1086/525258. （原始内容存档 (PDF)于2023-09-21）.
Denning DW. Echinocandins and pneumocandins--a new antifungal class with a novel mode of action. The Journal of Antimicrobial Chemotherapy. November 1997, 40 (5): 611–614. PMID 9421307. doi:10.1093/jac/dkf045 .
Shao L, Li J, Liu A, Chang Q, Lin H, Chen D. Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains. Applied and Environmental Microbiology. February 2013, 79 (4): 1126–1133. Bibcode:2013ApEnM..79.1126S. PMC 3568618 . PMID 23220968. doi:10.1128/AEM.02792-12.

drugs.com

Anidulafungin Pregnancy and Breastfeeding Warnings. Drugs.com. 2023-10-30 [2024-07-11]. （原始内容存档于2024-07-10）.

europa.eu

ec.europa.eu

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (PDF). European Medicines Agency. [2024-07-11]. （原始内容存档 (PDF)于2024-07-10）.

ema.europa.eu

Anidulafungin (PDF). EMA Europa. 2007 [2024-07-25]. （原始内容 (PDF)存档于2018-06-19）.

fda.gov

accessdata.fda.gov

HIGHLIGHTS OF PRESCRIBING INFORMATION for ERAXIS. (PDF). Pfizer. [2024-0726]. （原始内容存档 (PDF)于2024-09-27）.

fda.gov

FDA Approves New Treatment for Fungal Infections. FDA News Release. Food and Drug Administration. 2006-02-21 [2009-08-01]. （原始内容存档于2009-07-10）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.

harvard.edu

ui.adsabs.harvard.edu

Shao L, Li J, Liu A, Chang Q, Lin H, Chen D. Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains. Applied and Environmental Microbiology. February 2013, 79 (4): 1126–1133. Bibcode:2013ApEnM..79.1126S. PMC 3568618 . PMID 23220968. doi:10.1128/AEM.02792-12.

manchester.ac.uk

pure.manchester.ac.uk

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (PDF). Clinical Infectious Diseases. February 2008, 46 (3): 327–360 [2024-07-25]. PMID 18177225. S2CID 8789905. doi:10.1086/525258. （原始内容存档 (PDF)于2023-09-21）.

nih.gov

ncbi.nlm.nih.gov

Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrobial Agents and Chemotherapy. June 2004, 48 (6): 2021–2024. PMC 415613 . PMID 15155194. doi:10.1128/AAC.48.6.2021-2024.2004.
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Journal of Clinical Microbiology. November 2005, 43 (11): 5425–5427. PMC 1287823 . PMID 16272464. doi:10.1128/JCM.43.11.5425-5427.2005.
Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrobial Agents and Chemotherapy. November 2005, 49 (11): 4795–4797. PMC 1280139 . PMID 16251335. doi:10.1128/AAC.49.11.4795-4797.2005.
Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and Outcomes Research. January 2017, 9: 39–47. PMC 5221484 . PMID 28115858. doi:10.2147/CEOR.S122177 .
Zida A, Bamba S, Yacouba A, Ouedraogo-Traore R, Guiguemdé RT. Anti-Candida albicans natural products, sources of new antifungal drugs: A review. Journal de Mycologie Médicale. March 2017, 27 (1): 1–19. PMID 27842800. doi:10.1016/j.mycmed.2016.10.002.
Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. European Journal of Medical Research. April 2011, 16 (4): 159–166. PMC 3352072 . PMID 21486730. doi:10.1186/2047-783x-16-4-159 .
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. American Journal of Health-System Pharmacy. April 2005, 62 (8): 834–837. PMID 15821277. doi:10.1093/ajhp/62.8.834 .
Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clinical Therapeutics. June 2005, 27 (6): 657–673. PMID 16117974. doi:10.1016/j.clinthera.2005.06.010.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (PDF). Clinical Infectious Diseases. February 2008, 46 (3): 327–360 [2024-07-25]. PMID 18177225. S2CID 8789905. doi:10.1086/525258. （原始内容存档 (PDF)于2023-09-21）.
Denning DW. Echinocandins and pneumocandins--a new antifungal class with a novel mode of action. The Journal of Antimicrobial Chemotherapy. November 1997, 40 (5): 611–614. PMID 9421307. doi:10.1093/jac/dkf045 .
Shao L, Li J, Liu A, Chang Q, Lin H, Chen D. Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains. Applied and Environmental Microbiology. February 2013, 79 (4): 1126–1133. Bibcode:2013ApEnM..79.1126S. PMC 3568618 . PMID 23220968. doi:10.1128/AEM.02792-12.

pfizer.com

labeling.pfizer.com

Eraxis (anidulafungin) for Injection, for Intravenous Use. Full Prescribing Information. Roerig (Division of Pfizer, Inc.), New York, NY 10017. [2016-11-11]. （原始内容存档于2016-03-30）.

prnewswire.com

www2.prnewswire.com

Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/Candidemia. PRNewswire. 2005-08-18. （原始内容存档于2012-05-16）.
Vicuron Pharmaceuticals Stockholders Approve Merger With Pfizer. PRNewswire. 2005-08-15. （原始内容存档于2012-05-16）.

rxlist.com

Anidulafungin. RxList. 2023-10-30 [2024-07-11]. （原始内容存档于2024-07-10）.
Eraxis. RxList. 2009-06-24 [2009-08-01]. （原始内容存档于2018-01-16）.

semanticscholar.org

api.semanticscholar.org

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (PDF). Clinical Infectious Diseases. February 2008, 46 (3): 327–360 [2024-07-25]. PMID 18177225. S2CID 8789905. doi:10.1086/525258. （原始内容存档 (PDF)于2023-09-21）.

web.archive.org

International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 43 (PDF). World Health Organization. 2000 [11 November 2016]. （原始内容存档 (PDF)于2016-05-18）.
Eraxis (anidulafungin) for Injection, for Intravenous Use. Full Prescribing Information. Roerig (Division of Pfizer, Inc.), New York, NY 10017. [2016-11-11]. （原始内容存档于2016-03-30）.
HIGHLIGHTS OF PRESCRIBING INFORMATION for ERAXIS. (PDF). Pfizer. [2024-0726]. （原始内容存档 (PDF)于2024-09-27）.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (PDF). European Medicines Agency. [2024-07-11]. （原始内容存档 (PDF)于2024-07-10）.
Anidulafungin Pregnancy and Breastfeeding Warnings. Drugs.com. 2023-10-30 [2024-07-11]. （原始内容存档于2024-07-10）.
Anidulafungin. RxList. 2023-10-30 [2024-07-11]. （原始内容存档于2024-07-10）.
Eraxis. RxList. 2009-06-24 [2009-08-01]. （原始内容存档于2018-01-16）.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (PDF). Clinical Infectious Diseases. February 2008, 46 (3): 327–360 [2024-07-25]. PMID 18177225. S2CID 8789905. doi:10.1086/525258. （原始内容存档 (PDF)于2023-09-21）.
Anidulafungin (PDF). EMA Europa. 2007 [2024-07-25]. （原始内容 (PDF)存档于2018-06-19）.
Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/Candidemia. PRNewswire. 2005-08-18. （原始内容存档于2012-05-16）.
Vicuron Pharmaceuticals Stockholders Approve Merger With Pfizer. PRNewswire. 2005-08-15. （原始内容存档于2012-05-16）.
FDA Approves New Treatment for Fungal Infections. FDA News Release. Food and Drug Administration. 2006-02-21 [2009-08-01]. （原始内容存档于2009-07-10）.

who.int

International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names: List 43 (PDF). World Health Organization. 2000 [11 November 2016]. （原始内容存档 (PDF)于2016-05-18）.